Singapore markets closed

BCRX Jan 2024 8.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
1.9000-0.1000 (-5.00%)
As of 03:21PM EDT. Market open.
Full screen
Previous close2.0000
Expiry date2024-01-19
Day's range1.9000 - 1.9000
Contract rangeN/A
Open interest2.4k
  • Motley Fool

    Why Shares of BioCryst Pharmaceuticals Jumped Today

    Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were up 12% Wednesday afternoon, a day after the commercial-stage biotech released full-year and fourth-quarter earnings. The stock dropped as much as 17.1% on Tuesday after the earnings report, but Wednesday, it bounced back as much as 14% over the day before. Needham upgraded the stock to "buy" from "hold," adding a $14 price target, and H.C. Wainwright analyst Andrew Fein set a price target of $30 on the stock and reiterated his buy rating.

  • Motley Fool

    Why BioCryst Pharmaceuticals Stock Is Sinking Today

    Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are sinking today, down by 17.1% as of 11:09 a.m. ET. The big decline came after the drugmaker announced its fourth-quarter and full-year 2022 results before the market opened. BioCryst reported Q4 revenue of $79.5 million, up from $47.2 million in the prior-year period.

  • Motley Fool

    BioCryst Pharmaceuticals (BCRX) Q4 2022 Earnings Call Transcript

    Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; chief commercial officer, Charlie Gayer; and chief R&D officer, Dr. 2022 was another outstanding year for ORLADEYO as we doubled sales in our second full year of launch on top of the fantastic start we had in the first year.